JP2020530831A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020530831A5 JP2020530831A5 JP2019572817A JP2019572817A JP2020530831A5 JP 2020530831 A5 JP2020530831 A5 JP 2020530831A5 JP 2019572817 A JP2019572817 A JP 2019572817A JP 2019572817 A JP2019572817 A JP 2019572817A JP 2020530831 A5 JP2020530831 A5 JP 2020530831A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- hormone
- agent according
- crf
- receptor antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 27
- 229940124597 therapeutic agent Drugs 0.000 claims 27
- 208000005676 Adrenogenital syndrome Diseases 0.000 claims 12
- 208000008448 Congenital adrenal hyperplasia Diseases 0.000 claims 12
- 239000005556 hormone Substances 0.000 claims 12
- 229940088597 hormone Drugs 0.000 claims 12
- 239000002464 receptor antagonist Substances 0.000 claims 10
- 229940044551 receptor antagonist Drugs 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 9
- DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 claims 5
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 claims 5
- 101800000414 Corticotropin Proteins 0.000 claims 5
- 102100027467 Pro-opiomelanocortin Human genes 0.000 claims 5
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims 5
- 229960000258 corticotropin Drugs 0.000 claims 5
- 239000003862 glucocorticoid Substances 0.000 claims 3
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000010419 fine particle Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- DBPWSSGDRRHUNT-UHFFFAOYSA-N 17alpha-hydroxy progesterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(=O)C)(O)C1(C)CC2 DBPWSSGDRRHUNT-UHFFFAOYSA-N 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 229960005471 androstenedione Drugs 0.000 claims 1
- AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229950000801 hydroxyprogesterone caproate Drugs 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023146415A JP7573080B2 (ja) | 2017-08-14 | 2023-09-08 | 副腎皮質刺激ホルモン放出因子受容体拮抗薬 |
| JP2024179270A JP2025020148A (ja) | 2017-08-14 | 2024-10-11 | 副腎皮質刺激ホルモン放出因子受容体拮抗薬 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762545406P | 2017-08-14 | 2017-08-14 | |
| US62/545,406 | 2017-08-14 | ||
| PCT/US2018/046760 WO2019036503A1 (en) | 2017-08-14 | 2018-08-14 | CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023146415A Division JP7573080B2 (ja) | 2017-08-14 | 2023-09-08 | 副腎皮質刺激ホルモン放出因子受容体拮抗薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020530831A JP2020530831A (ja) | 2020-10-29 |
| JP2020530831A5 true JP2020530831A5 (https=) | 2021-09-24 |
| JP7398963B2 JP7398963B2 (ja) | 2023-12-15 |
Family
ID=65362494
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572817A Active JP7398963B2 (ja) | 2017-08-14 | 2018-08-14 | 副腎皮質刺激ホルモン放出因子受容体拮抗薬 |
| JP2023146415A Active JP7573080B2 (ja) | 2017-08-14 | 2023-09-08 | 副腎皮質刺激ホルモン放出因子受容体拮抗薬 |
| JP2024179270A Pending JP2025020148A (ja) | 2017-08-14 | 2024-10-11 | 副腎皮質刺激ホルモン放出因子受容体拮抗薬 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023146415A Active JP7573080B2 (ja) | 2017-08-14 | 2023-09-08 | 副腎皮質刺激ホルモン放出因子受容体拮抗薬 |
| JP2024179270A Pending JP2025020148A (ja) | 2017-08-14 | 2024-10-11 | 副腎皮質刺激ホルモン放出因子受容体拮抗薬 |
Country Status (11)
| Country | Link |
|---|---|
| US (9) | US20210361664A1 (https=) |
| EP (1) | EP3628005A4 (https=) |
| JP (3) | JP7398963B2 (https=) |
| KR (2) | KR20250022913A (https=) |
| CN (2) | CN118845788A (https=) |
| AU (2) | AU2018317398A1 (https=) |
| BR (1) | BR112020002967A2 (https=) |
| CA (1) | CA3064464A1 (https=) |
| EA (1) | EA202090450A1 (https=) |
| MX (2) | MX2019015320A (https=) |
| WO (1) | WO2019036503A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015112642A1 (en) | 2014-01-21 | 2015-07-30 | Neurocrine Biosciences, Inc. | Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia |
| CN118845788A (zh) | 2017-08-14 | 2024-10-29 | 云杉生物科学公司 | 促肾上腺皮质激素释放因子受体拮抗剂 |
| EP4438124A3 (en) | 2018-04-27 | 2024-12-18 | Spruce Biosciences, Inc. | Methods for treating testicular and ovarian adrenal rest tumors |
| CA3121920A1 (en) | 2018-12-07 | 2020-06-11 | Neurocrine Biosciences, Inc. | Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia |
| TW202116324A (zh) * | 2019-07-19 | 2021-05-01 | 美商雲杉生物科技股份有限公司 | 治療先天性腎上腺增生之方法 |
| JP7623365B2 (ja) | 2019-09-27 | 2025-01-28 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | Ｃｒｆ受容体アンタゴニストおよび使用方法 |
| BR112023002497A2 (pt) * | 2020-08-12 | 2023-05-02 | Spruce Biosciences Inc | Métodos e composições para tratamento da síndrome dos ovários policísticos |
| JP2023540223A (ja) * | 2020-08-26 | 2023-09-22 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | Ｃｒｆ受容体アンタゴニストおよび使用方法 |
| US11708372B2 (en) | 2021-11-19 | 2023-07-25 | Spruce Biosciences, Inc. | Crystalline composition of tildacerfont and methods of use and preparation thereof |
| WO2025188842A1 (en) * | 2024-03-08 | 2025-09-12 | Spruce Biosciences, Inc. | Amorphous solid dispersion of tildacerfont formulations |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE177101T1 (de) | 1992-12-17 | 1999-03-15 | Pfizer | Pyrrolopyrimidine als crf antagonisten |
| JP3356291B2 (ja) | 1996-02-07 | 2002-12-16 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｃｒｆレセプター拮抗薬としてのピラゾロピリミジン類 |
| IL127871A0 (en) | 1996-07-24 | 1999-10-28 | Du Pont Pharm Co | Azolo triazines and pyrimidines |
| HU228962B1 (en) | 1996-07-24 | 2013-07-29 | Bristol Myers Squibb Pharma Co | Azolo triazines, pharmaceutical compositions containing them and use of the compounds |
| IL127566A0 (en) | 1996-08-28 | 1999-10-28 | Pfizer | Substituted 6,5-hetero- bicyclic derivatives |
| EP1049699B1 (en) | 1998-01-28 | 2004-04-21 | Bristol-Myers Squibb Pharma Company | Pyrazolotriazines as crf antagonists |
| IL137019A (en) | 1998-01-28 | 2010-11-30 | Du Pont Pharm Co | 2,7 - dimethyl - 4 - (substituted amino) - 8 - arylpyrazolo [1,5-a] triazine derivatives and pharmaceutical compositions containing them |
| EP1040831A3 (en) | 1999-04-02 | 2003-05-02 | Pfizer Products Inc. | Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death |
| WO2000059908A2 (en) | 1999-04-06 | 2000-10-12 | Du Pont Pharmaceuticals Company | Pyrazolopyrimidines as crf antagonists |
| EP1218381B1 (en) | 1999-09-30 | 2006-12-06 | Neurogen Corporation | AMINO SUBSTITUTED PYRAZOLO¬1,5-a|-1,5-PYRIMIDINES AND PYRAZOLO¬1,5-a|-1,3,5-TRIAZINES |
| JP2003516353A (ja) | 1999-12-08 | 2003-05-13 | ファルマシア コーポレイション | ヴァルデコキシブ組成物 |
| BR0208357A (pt) | 2001-03-13 | 2004-06-29 | Bristol Myers Squibb Pharma Co | Composto, composição farmacêutica, método de antagonização de um receptor de fator de liberação de corticotropina (crf), método de tratamento de disfunção, método de triagem de ligantes, método de detecção de receptores de crf, método de inibição da ligação de crf, artigo industrializado e usos do composto |
| US20050085479A1 (en) | 2003-08-27 | 2005-04-21 | Pharmacia Corporation | Mediated central nervous system compositions of a cyclooxygenase-2 selective inhibitor and a corticotropin releasing factor antagonist for the treatment of ischemic disorders or injury |
| CA2547639A1 (en) | 2003-12-02 | 2005-06-16 | B&B Beheer Nv | Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists |
| CA2550948A1 (en) | 2003-12-22 | 2005-07-14 | Sb Pharmco Puerto Rico Inc. | Crf receptor antagonists and methods relating thereto |
| WO2005079868A2 (en) | 2004-02-13 | 2005-09-01 | Sb Pharmco Puerto Rico Inc | Crf receptor antagonists, their preparations, their pharmaceutical composition and their uses |
| WO2005079807A1 (en) | 2004-02-13 | 2005-09-01 | Pfizer Products Inc. | Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists |
| WO2006124047A2 (en) * | 2004-08-13 | 2006-11-23 | Emisphere Technologies, Inc. | Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent |
| AU2006227300B2 (en) | 2005-03-21 | 2012-02-02 | Eli Lilly And Company | Imidazopyridazine compounds |
| CN101516835A (zh) | 2006-07-19 | 2009-08-26 | 俄亥俄州立大学研究基金会 | 选择性雄激素受体调节剂、它们的类似物和衍生物以及它们的用途 |
| EP2094709B1 (en) * | 2006-09-20 | 2010-09-15 | Eli Lilly And Company | Thiazole pyrazolopyrimidines as crf1 receptor antagonists |
| AU2007297481B2 (en) | 2006-09-20 | 2012-03-08 | Eli Lilly And Company | Thiophene pyrazolopyrimidine compounds |
| US8952207B2 (en) | 2007-09-11 | 2015-02-10 | The University Of Houston System | Copper-catalyzed C—H bond arylation |
| US8318813B2 (en) | 2007-09-13 | 2012-11-27 | Lcs Group, Llc | Method of treating binge eating disorder |
| WO2010039678A1 (en) | 2008-10-02 | 2010-04-08 | Eli Lilly And Company | Thiazolyl-pyrazolopyrimidine compounds as synthetic intermediates and related synthetic processes |
| EP4718073A2 (en) * | 2008-12-24 | 2026-04-01 | Quest Diagnostics Investments Incorporated | Mass spectrometry assay for congenital adrenal hyperplasia |
| PL2519230T3 (pl) * | 2009-12-31 | 2019-05-31 | Marius Pharmaceuticals Llc | Modulacja rozpuszczalności, stabilności, absorpcji, metabolizmu i profilu farmakokinetycznego leków lipofilowych przez sterole |
| US9750568B2 (en) | 2012-03-08 | 2017-09-05 | Medtronic Ardian Luxembourg S.A.R.L. | Ovarian neuromodulation and associated systems and methods |
| HK1207304A1 (en) | 2012-04-23 | 2016-01-29 | Hmnc Value Gmbh | Crhr1 antagonists for use in the treatment of patients having crh overactivity |
| WO2015112642A1 (en) * | 2014-01-21 | 2015-07-30 | Neurocrine Biosciences, Inc. | Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia |
| AU2016242867B2 (en) | 2015-03-31 | 2020-11-05 | May Health Us Inc. | Methods and systems for the manipulation of ovarian tissues |
| CN118845788A (zh) | 2017-08-14 | 2024-10-29 | 云杉生物科学公司 | 促肾上腺皮质激素释放因子受体拮抗剂 |
| EA202090321A1 (ru) | 2017-08-14 | 2020-09-24 | Спрюс Биосайнсес, Инк. | Антагонисты рецептора кортикотропин-рилизинг фактора |
| EP4438124A3 (en) | 2018-04-27 | 2024-12-18 | Spruce Biosciences, Inc. | Methods for treating testicular and ovarian adrenal rest tumors |
| CA3121920A1 (en) | 2018-12-07 | 2020-06-11 | Neurocrine Biosciences, Inc. | Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia |
| US20200255436A1 (en) | 2019-02-12 | 2020-08-13 | Spruce Biosciences, Inc. | Corticotropin releasing factor receptor antagonists |
| TW202116324A (zh) | 2019-07-19 | 2021-05-01 | 美商雲杉生物科技股份有限公司 | 治療先天性腎上腺增生之方法 |
| BR112023002497A2 (pt) | 2020-08-12 | 2023-05-02 | Spruce Biosciences Inc | Métodos e composições para tratamento da síndrome dos ovários policísticos |
| US11708372B2 (en) | 2021-11-19 | 2023-07-25 | Spruce Biosciences, Inc. | Crystalline composition of tildacerfont and methods of use and preparation thereof |
| MX2024006064A (es) | 2021-11-19 | 2024-05-30 | Spruce Biosciences Inc | Composicion cristalina de tildacerfont y metodos de uso y preparacion de la misma. |
-
2018
- 2018-08-14 CN CN202410709847.0A patent/CN118845788A/zh active Pending
- 2018-08-14 JP JP2019572817A patent/JP7398963B2/ja active Active
- 2018-08-14 MX MX2019015320A patent/MX2019015320A/es unknown
- 2018-08-14 EP EP18846689.0A patent/EP3628005A4/en active Pending
- 2018-08-14 CN CN201880038569.3A patent/CN110996943A/zh active Pending
- 2018-08-14 KR KR1020257004457A patent/KR20250022913A/ko active Pending
- 2018-08-14 WO PCT/US2018/046760 patent/WO2019036503A1/en not_active Ceased
- 2018-08-14 BR BR112020002967-0A patent/BR112020002967A2/pt not_active Application Discontinuation
- 2018-08-14 CA CA3064464A patent/CA3064464A1/en active Pending
- 2018-08-14 KR KR1020207004095A patent/KR20200040761A/ko not_active Ceased
- 2018-08-14 AU AU2018317398A patent/AU2018317398A1/en not_active Abandoned
- 2018-08-14 US US16/639,541 patent/US20210361664A1/en not_active Abandoned
- 2018-08-14 EA EA202090450A patent/EA202090450A1/ru unknown
-
2019
- 2019-04-18 US US16/388,620 patent/US10849908B2/en active Active
- 2019-12-16 MX MX2023000501A patent/MX2023000501A/es unknown
-
2020
- 2020-10-05 US US17/063,592 patent/US11344557B2/en active Active
- 2020-10-22 US US17/078,054 patent/US11007201B2/en active Active
-
2021
- 2021-06-25 US US17/359,411 patent/US11351177B2/en active Active
- 2021-06-25 US US17/359,414 patent/US11311549B2/en active Active
-
2022
- 2022-01-27 US US17/586,228 patent/US20220143037A1/en not_active Abandoned
- 2022-12-09 US US18/078,649 patent/US20230321112A1/en active Pending
-
2023
- 2023-01-13 AU AU2023200189A patent/AU2023200189B2/en active Active
- 2023-04-26 US US18/307,718 patent/US12115166B2/en active Active
- 2023-09-08 JP JP2023146415A patent/JP7573080B2/ja active Active
-
2024
- 2024-10-11 JP JP2024179270A patent/JP2025020148A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020530831A5 (https=) | ||
| Patel et al. | Effect of olopatadine-mometasone combination nasal spray on seasonal allergic rhinitis symptoms in an environmental exposure chamber study | |
| JP2019509351A5 (https=) | ||
| JP2016538270A5 (https=) | ||
| EP3923920A1 (en) | Ketamine for the treatment of postpartum symptoms and disorders | |
| JP2009215293A5 (https=) | ||
| Tseng et al. | Important drug-drug interactions in HIV-infected persons on antiretroviral therapy: an update on new interactions between HIV and non-HIV drugs | |
| KR20200038951A (ko) | 코티코트로핀 방출 인자 수용체 길항제 | |
| JP2020516646A5 (https=) | ||
| JP2019525948A5 (https=) | ||
| KR20200040761A (ko) | 코티코트로핀 방출 인자 수용체 길항제 | |
| IL320452A (en) | Combination therapy for prostate cancer | |
| JP2017529388A5 (https=) | ||
| JP2017533220A5 (https=) | ||
| JP2017526697A5 (https=) | ||
| US20140329782A1 (en) | Combined therapeutic agent | |
| JP2020500864A5 (https=) | ||
| Baughman et al. | Newer therapies for cutaneous sarcoidosis: the role of thalidomide and other agents | |
| RU2619869C2 (ru) | Композиция гидрокортизона с контролируемым высвобождением | |
| KR20220164539A (ko) | SARS-CoV-2 감염의 치료를 위한 25-히드록시비타민 D | |
| TW200902027A (en) | Compositions and methods for treating medical conditions | |
| Spies et al. | Prednisone chronotherapy | |
| Deodhar et al. | POS0939 Bimekizumab in patients with active non-radiographic axial spondyloarthritis: 24-week efficacy & safety from be mobile 1, a phase 3, multicentre, randomised, placebo‑controlled study | |
| Sands et al. | New life in a sleeper: thalidomide and Crohn's disease | |
| CA3113468A1 (en) | Grapiprant unit dosage forms |